Biocon Q1 results, quarter to Jun 2026

NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap

Biocon Limited · Face value ₹5 · Listed Apr 2004

₹351.80₹0.10 (0.03%)BSE ₹352.00

Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.

30 Oct: open ₹352.70, high ₹355.50, low ₹348.70

52-week range of traded prices to 30 Oct 2026

₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026

Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar

Market cap: ₹57,333 Cr173rd largest listed
P/E: 115.75
P/E without one-offs: 64.09
P/B: 1.68
Dividend yield: 0.14%
ROE: 1.8%
ROE without one-offs: 3.2%
ROCE: 2.9%
Debt to equity: 0.40
Volume, NSE: 20,63,63747.1% delivered

Biocon filed its Q1 results for the quarter to Jun 2026 on 5 Aug 2026 at 5:20 pm, consolidated: the company and its subsidiaries together.

Q1 results, quarter to Jun 2026

₹ crore.Biocon annual results and balance sheet

Revenue: ₹4,336 Cr+10.0% on a year ago · −4.0% on the quarter before
Operating profit: ₹847 Cr+13.1% on a year ago · −17.0% on the quarter before
Net profit: ₹137 Cr+53.4% on a year ago · −31.1% on the quarter before
Earnings per share: ₹0.87+234.6% on a year ago · +10.1% on the quarter before
Operating margin: 19.5%
Net margin: 3.2%

From revenue to net profit, ₹ crore

Revenue4,336
Materials and goods−1,468
Employee costs−916
Other expenses−1,105
Operating profit847
Depreciation−547
Other income+55
One-off items−14
Finance costs−213
Profit before tax128
Tax+9.2
Net profit137

Biocon results by quarter

Consolidated: the company and its subsidiaries together. Latest quarter to Jun 2026. Results for the quarter to Sep 2026 are due by 14 Nov 2026, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date

Revenue and net profit by quarter, ₹ crore

Revenue
Net profit
Loss

Peak revenue ₹4,517 Cr, quarter to Mar 2026; lowest ₹3,433 Cr, quarter to Jun 2024A loss in 1 of the 12 quarters shown

Operating and net margin by quarter, per cent

Operating margin
Net margin

₹ crore	Sep 2021	Dec 2021Q3	Mar 2022	Jun 2022Q1	Sep 2022	Dec 2022Q3	Mar 2023	Jun 2023Q1	Sep 2023	Dec 2023Q3	Mar 2024	Jun 2024Q1	Sep 2024Filed 30 Oct	Dec 2024Q3	Mar 2025Q4	Jun 2025Q1	Sep 2025Q2	Dec 2025Q3	Mar 2026Q4	Jun 2026Q1Filed 5 Aug
Revenue from operations	1,840	2,174	2,409	2,140	2,320	2,941	3,774	3,423	3,462	3,954	3,917	3,433	3,590	3,821	4,417	3,942	4,296	4,173	4,517	4,336
	1,395	1,686	1,817	1,740	1,849	2,297	2,777	2,708	2,721	3,027	3,001	2,813	2,905	3,070	3,339	3,193	3,460	3,340	3,496	3,489
Materials and goods bought	565	713	828	703	752	980	1,229	1,210	1,127	1,232	1,330	1,183	1,183	1,359	1,473	1,405	1,547	1,339	1,399	1,468
Employee costs	479	495	470	513	540	559	569	579	622	721	742	755	790	788	811	833	888	875	912	916
Other expenses	351	478	518	525	557	758	979	919	971	1,074	930	874	933	922	1,055	955	1,025	1,125	1,185	1,105
Operating profit before depreciation	446	488	592	399	471	644	997	714	742	927	916	620	685	752	1,078	749	835	834	1,020	847
Operating margin	24.2%	22.5%	24.6%	18.7%	20.3%	21.9%	26.4%	20.9%	21.4%	23.4%	23.4%	18.1%	19.1%	19.7%	24.4%	19.0%	19.4%	20.0%	22.6%	19.5%
Depreciation and amortisation	202	206	212	218	231	301	364	358	389	415	407	405	420	425	436	455	473	515	513	547
Other income	105	48	67	78	65	79	155	94	158	566	49	1,135	33	35	37	80	93	117	53	55
Finance costs	23	15	11	20	30	120	249	233	248	267	227	236	226	223	212	277	272	210	232	213
Profit before one-off items and tax	327	316	437	240	274	302	540	217	263	811	331	1,114	72	138	466	97	183	226	328	141
One-off items	−70	0	−41	0	−17	−271	−3	0	−24	21	−9	32	26	18	20	0	−12	−293	−80	−14
Profit before tax	257	316	396	240	257	30	537	217	239	832	322	1,146	98	156	487	97	171	−68	248	128
	46	49	59	30	147	−5	82	35	42	55	96	284	71	75	27	8	39	−16	49	−9
Current tax	46	49	59	30	147	−5	82	43	52	83	136	225	24	114	6	67	59	67	251	116
Deferred tax	0	0	0	0	0	0	0	−9	−11	−28	−40	58	47	−39	21	−59	−21	−83	−202	−125
Tax rate	18.0%	15.6%	14.8%	12.3%	57.2%	−15.9%	15.3%	16.0%	17.4%	6.6%	29.9%	24.8%	72.5%	48.0%	5.6%	7.9%	22.5%	–	19.8%	−7.2%
Share of profit of joint ventures and associates	−51	−47	−53	−43	−28	−56	−40	−33	−24	−24	−3	–	–	–	–	–	–	–	–	–
	160	220	284	167	82	−21	415	149	173	753	223	862	27	81	459	89	133	−52	199	137
Belonging to the company's shareholders	138	187	239	144	47	−42	313	101	126	660	136	660	−16	25	345	31	85	144	126	141
Belonging to outside owners of subsidiaries	21	33	45	23	35	21	101	48	47	93	87	202	43	56	115	58	48	−196	73	−4
Other comprehensive income	78	−1	62	−65	18	190	−66	171	190	43	−17	42	522	57	−184	−206	970	306	974	789
Total comprehensive income	238	219	346	102	100	169	349	320	363	796	206	903	549	138	276	−116	1,103	254	1,173	926
Net margin	8.7%	10.1%	11.8%	7.8%	3.5%	−0.7%	11.0%	4.4%	5.0%	19.1%	5.7%	25.1%	0.8%	2.1%	10.4%	2.3%	3.1%	−1.2%	4.4%	3.2%
Net margin without joint ventures and associates	11.4%	12.3%	14.0%	9.8%	4.7%	1.2%	12.0%	5.3%	5.7%	19.7%	5.8%	–	–	–	–	–	–	–	–	–
Earnings per share	₹1.16	₹1.57	₹2.00	₹1.21	₹0.39	−₹0.35	₹2.62	₹0.85	₹1.05	₹5.52	₹1.13	₹5.51	−₹0.13	₹0.21	₹2.88	₹0.26	₹0.66	₹1.08	₹0.79	₹0.87
Diluted earnings per share	₹1.16	₹1.56	₹1.99	₹1.21	₹0.39	−₹0.35	₹2.62	₹0.85	₹1.05	₹5.51	₹1.13	₹5.51	−₹0.13	₹0.21	₹2.87	₹0.26	₹0.65	₹1.07	₹0.79	₹0.87

Earnings per share in rupees, restated for later splits and bonuses.

Segment results by quarter

Consolidated, ₹ crore, quarters to Jun 2026.Biocon segment results by year

Biosimilars
Revenue, ₹ crore
1,969
2,483
2,358
2,083
2,182
2,289
2,463
2,458
2,721
2,497
2,756
2,856
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
−15
196
90
1,065
−17
1
39
96
112
112
148
171
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Generics
Revenue, ₹ crore
676
703
718
659
624
686
1,048
697
774
851
847
760
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
66
50
50
17
−9
−14
181
−67
−33
−23
−12
−31
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Services
Revenue, ₹ crore
736
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Profit, ₹ crore
−6
Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26

₹ crore	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue of all businesses	3,555	4,040	3,993	3,532	3,697	3,919	4,529	4,029	4,405	4,265	4,639	4,351
Company revenue, as in its results	3,462	3,954	3,917	3,433	3,590	3,821	4,417	3,942	4,296	4,173	4,517	4,336
Revenue	1,969	2,483	2,358	2,083	2,182	2,289	2,463	2,458	2,721	2,497	2,756	2,856
Revenue growth	97.4%	64.8%	12.2%	3.4%	10.8%	−7.8%	4.5%	18.0%	24.7%	9.1%	11.9%	16.2%
Profit	−15	196	90	1,065	−17	1	39	96	112	112	148	171
Profit growth	–	92.3%	−40.7%	4,281.9%	–	−99.6%	−56.5%	−91.0%	–	15,857.1%	276.3%	78.5%
Margin	−0.8%	7.9%	3.8%	51.1%	−0.8%	0.0%	1.6%	3.9%	4.1%	4.5%	5.4%	6.0%
Assets	42,448	42,915	43,144	43,295	43,679	44,715	44,440	44,711	46,106	46,231	47,888	48,653
Liabilities	25,083	25,297	25,734	24,381	24,711	24,718	23,912	22,460	22,927	21,999	21,179	21,489
Capital employed	17,365	17,618	17,409	18,914	18,967	19,997	20,528	22,251	23,179	24,232	26,709	27,164
Revenue	–	–	–	–	–	–	–	875	911	917	1,037	–
Profit	–	–	–	–	–	–	–	101	85	99	202	–
Margin	–	–	–	–	–	–	–	11.6%	9.4%	10.8%	19.5%	–
Assets	–	–	–	–	–	–	–	6,675	6,542	6,465	7,055	–
Liabilities	–	–	–	–	–	–	–	1,828	1,807	1,699	2,215	–
Capital employed	–	–	–	–	–	–	–	4,847	4,735	4,766	4,840	–
Revenue	676	703	718	659	624	686	1,048	697	774	851	847	760
Revenue growth	8.6%	−2.0%	0.3%	−5.9%	−7.7%	−2.4%	45.8%	5.6%	23.9%	24.0%	−19.2%	9.1%
Profit	66	50	50	17	−9	−14	181	−67	−33	−23	−12	−31
Profit growth	22.7%	−31.3%	−32.6%	−73.6%	–	–	258.7%	–	–	–	–	–
Margin	9.8%	7.0%	7.0%	2.6%	−1.4%	−2.0%	17.3%	−9.6%	−4.2%	−2.7%	−1.5%	−4.1%
Assets	6,322	6,480	7,107	6,824	7,897	7,884	8,327	7,953	8,742	9,066	8,993	9,387
Liabilities	1,985	2,052	1,976	2,009	2,540	2,687	3,100	2,932	3,350	3,633	3,756	3,866
Capital employed	4,337	4,428	5,131	4,816	5,357	5,196	5,227	5,022	5,392	5,433	5,237	5,521
Revenue	–	–	–	–	–	–	–	–	–	–	–	736
Profit	–	–	–	–	–	–	–	–	–	–	–	−6
Margin	–	–	–	–	–	–	–	–	–	–	–	−0.8%
Assets	–	–	–	–	–	–	–	–	–	–	–	6,745
Liabilities	–	–	–	–	–	–	–	–	–	–	–	1,879
Capital employed	–	–	–	–	–	–	–	–	–	–	–	4,866
Revenue	910	854	917	790	891	944	1,018	–	–	–	–	–
Revenue growth	18.5%	8.6%	−7.8%	−2.3%	−2.1%	10.6%	11.0%	–	–	–	–	–
Profit	158	142	209	69	137	181	241	–	–	–	–	–
Profit growth	21.6%	1.4%	−9.4%	−43.6%	−13.2%	27.4%	15.1%	–	–	–	–	–
Margin	17.4%	16.6%	22.8%	8.8%	15.4%	19.2%	23.6%	–	–	–	–	–
Assets	5,846	5,716	6,152	6,112	6,136	6,087	6,796	–	–	–	–	–
Liabilities	1,955	1,688	1,894	1,742	1,741	1,605	2,069	–	–	–	–	–
Capital employed	3,891	4,028	4,258	4,370	4,396	4,482	4,727	–	–	–	–	–
	0	0	0	0	–	0	0	–	–	–	–	–
Profit	55	425	0	0	–	0	0	–	–	–	–	–
Assets	221	625	0	0	–	0	0	–	–	–	–	–
Liabilities	41	32	0	0	–	0	0	–	–	–	–	–
Capital employed	180	593	0	0	–	0	0	–	–	–	–	–

Profit is before tax and finance costs, the way companies report their segments.

Q1 results, quarter to Jun 2026

From revenue to net profit, ₹ crore

Biocon results by quarter

Revenue and net profit by quarter, ₹ crore

Operating and net margin by quarter, per cent

Segment results by quarter

Biosimilars

Generics

Services